DEA Halts Marijuana Rescheduling Hearing Due to GAO Report
The Drug Enforcement Administration (DEA) has paused a hearing on reclassifying marijuana from Schedule I to Schedule III under the Trump administration's request. The decision follows a recent Government Accountability Office (GAO) report that identified significant gaps in the federal drug scheduling process, raising concerns about its integrity and transparency. This pause highlights ongoing scrutiny of how controlled substances are classified at the federal level. Critics argue that current procedures lack sufficient scientific review and public input, which could affect future rescheduling decisions for other drugs as well. The DEA's decision to halt proceedings underscores a broader debate over drug policy reform in the U.S., particularly amid growing support for marijuana legalization. The outcome of this hearing has potential implications not only for federal regulation but also for state-level cannabis industries and investors, especially if it leads to changes that could impact legal frameworks or market access.
Topics: DEA federal regulation GAO report marijuana